medigraphic.com
ISSN 1025-0255 (Electronic)

2015, Number 5

<< Back Next >>

AMC 2015; 19 (5)

Results of the use of the intravitreous triamcinolone in patients with rubeosis iridis

Chávez PI, de Varona LL, Coellar TOL, González VD

Language: Spanish
References: 34
Page: 431-440
PDF size: 742.41 Kb.


ABSTRACT

Background: rubeosis iridis is generally associated to different diseases that produce lack of oxygen in the retina. It is the most frequent and early complication of many vascular diseases of the posterior segment that causes irreversible loss of vision if it is not early diagnosed and treated.
Objective: to describe the behavior of rubeosis iridis after the treatment with intravitreous triamcinolone.
Method: a descriptive, longitudinal study was conducted in patients with rubeosis iridis who came to the retina consultation of Carlos J. Finlay Ophthalmology Center from June 2013 to June 2014. The universe of the study was composed of 25 patients and the non-probabilistic sample by 30 eyes that matched the inclusion criteria. A form was applied to collect the data. The results were related to the following variables: ocular tension, symptoms, diseases that cause rubeosis iridis and rubeosis degrees.
Results: ocular tension stabilized with the treatment applied. The most frequent symptom was pain. Proliferative diabetic retinopathy was the most frequent disease in the 40 % of the patients, followed by thrombosis of the central retinal vein. More than the half of the patients improved their condition, some of them with a complete regression.
Conclusions: intraocular tension improved after the treatment with intravitreous triamcinolone. Symptoms disappeared in more than the half of the patients. Proliferative diabetic retinopathy was the most frequent disease that caused rubeosis iridis. This sign disappeared in more than the half of the patients after the treatment.


REFERENCES

  1. Verdaguer J, Zanolli M, Sepúlveda G, García de los Ríos M, Domínguez A. Natural history of diabe-tic retinopathy in a retrospective cohort of type 1 diabetics. Rev Med Chil. 2009 Sep;137(9):1145-52.

  2. Esteffan Karim C, Navea C, Ageno Yannina E. Retinopatía Diabética. Rev cienc salud. Dic 2008;12(1):49-54.

  3. Kanski J. Oftalmología clínica. 5ed. España: Edi-torial Eselvler; 2005.

  4. Rey Estévez BN, Varela Gener E, Alba Carcasés Y, Bibianes Maché MC, García Galí M. Glaucoma y retinopatía en pacientes con diabetes mellitas. ME-DISAN [Internet]. 2007 [citado 15 Abr 2011];11(2):[aprox. 9 p.]. Disponible en: http//bvs.sld.cu/revistas/san/vol11_2_07/san07207.htm

  5. Canut MI, Alvarez A, Nadal J, Abreu R, Abreu JA, Pulido JS. Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma. Clin Ophthalmol. 2011;5:715-719.

  6. Spaide FR. Las inyecciones intravítrea de corti-coides sugeridas para el tratamiento de diversas enfermedades retinianas. Ophthalmology times. 2005;9(6):12-40.

  7. Raivio VE, Puska PM, Immonen IJR. Cyclophoto-coagulation with the transscleral contact red 670 nm diode laser in the treatment of glaucoma. Acta Ophthalmologica. 2008 Aug;86(5):558-64.

  8. Aiello LP, Brucker AJ, Chang S, Cunningham ET, Damico DJ, Flynn HW, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24:3-19.

  9. Gómez Ulla F, Basauri E, Arias L, Martínez Sanz F. Manejo de las inyecciones intravítreas. Arch Soc Esp Oftalmol [Internet]. 2009 [citado 15 Abr 2011];84(8):[aprox. 9 p.]. Disponible en: http://scielo.isciii.es/scielo.php?pid=S0365

  10. Eguía Martínez F, Rió Torres M, Capote Cabre-ra A, Ríos Casos R, Hernández Silva J, Gómez Ca-brera C. Manual de diagnóstico y tratamiento en Oftalmología. La Habana: Ecimed; 2009.

  11. Zacks DN, Johnson Mark WM. Combined Intra-vitreal Injection of Triamcinolone Acetonide and Panretinal Photocoagulation for Concomitant Dia-betic Macular Edema and Proliferative Diabetic Retinopathy. Retina. 2005 Feb-Mar;25(2):135-40.

  12. Machemer R, Sugita G. Treatment of intraocu-lar proliferations within intravítrea steroids. Trans Am Ophtahlmol Soc. 2004;77:171-80.

  13. Jaissle GB, Szurman P, Bartz-Schmidt KU. Empfehlung fur dies Durcgfuhrung von intravitrea-len Injektionen. Klin Monatsbl Augenheilkd. 2005;222:390-95.

  14. Arévalo JF, Fernández CF, Mendoza AJ, García RA, Arévalo FA. Triamcinolona intravítrea combi-nada con fotocoagulación láser en rejilla en pa-cientes con edema macular quístico y retinopatía diabética avanzada: estudio piloto. Arch Soc Espa-ñola Oftalmol. 2011;88(10):373-79.

  15. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeu-tics. Surv Ophthalmol. 2007 Sep-Oct;52(5):503-22.

  16. Martínez Carpio PA, Bonafonte Márquez E, He-redia García CD, Bonafonte Royo S. Eficacia y se-guridad de la inyección intravítrea de bevacizumab en el tratamiento del glaucoma neovascular: revi-sión sistemática. Arch Soc Esp Oftalmol [Internet].2008 [citado 15 Abr 2011];83:[aprox. 10 p]. Disponible en: http://scielo.isciii.es/scielo.php?pid=S0365

  17. Collignon NJ, Crommen J, Collignon-Brach J, Rakic JM. Low dose intravitreal triamcinolone ace-tonide in the treatment of neovasular glaucoma. Bull Soc Belge Ophtalmol. 2005; 298:5-10.

  18. Jonas JB, Hayler JK, Söfker A, Panda JS. Re-gression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glauco-ma.2001;10:284-7.

  19. Rey Estévez BN, Varela Gener E, Alba Carcasés Y, Bibianes Maché MC, García Galí M. Glaucoma y retinopatía en pacientes con diabetes mellitas. ME-DISAN [Internet]. 2007 [citado 15 Abr 2011];11(2):[aprox. 9 p.]. Disponible en: http//bvs.sld.cu/revistas/san/vol11_2_07/san07207.htm

  20. Yong T, Jonas JB. Intravitreal Triamcinolone. Ophthalmologica. J Int D'ophtalm. 2011; 225(1):1-20.

  21. Ober MD, Valijan S. The duration of effect of centrifuge concentrated intravitre. 2013 Apr;33(4): 768 - 87 .

  22. Rojas Rondón I, Rivas Canino MC, Eguias Martínez F, Rodríguez Masó S, D'Castro P, Ramos López M. Uso de la triamcinolona subtenoniana en pacientes con rubeosis del iris. Rev Cubana Oftalmol. 2008;21(2):24-34.

  23. García Galí M, Ricardo González J, Salvador Álvarez S, González Ramos M. Tratamiento del glaucoma neovascular con criocirugía. MEDISAN [Internet]. 1999 [citado 18 Jul 2013];3(3):[aprox. 3 p.]. Disponible en: http://www.bvs.sld.cu/revistas/san/vol3_3_99/san07399.htm

  24. Flyrn HJ, Smiddy WE. Diabetes and ocular dis-ease; past, present and future therapies. New York: American Academy of Ophthalmology; 2002.

  25. Beer PM, Bakry SJ, Singh RJ, Liu W, Peter GB, Miller M. Intraocular Concentration and pharmaco-kinetics of triamcinolone acetonide after a single intravitreal inyection. Departament of Ophthalmol-ogy, Lion Eye. Institute Medical. New York: Col-legealbany, USA; 2003.

  26. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion a prospective histo-pathology study of 29 eyes in 28 cases. Retina. 2005;25(5):27-55.

  27. Vaughan DG, Asbury P, Taylor R, Roldan E. Ophthalmology General. 16th ed. New York: McGraw Hill; 2004.

  28. Maia OO, Takahashi BS, Costa RA, Scott IU, Takahashi WY. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one year’s results of a ran-domized clinical trial. Am J Ophthalmol. 2009 Feb;147(2):291-97.

  29. Abraldes Rodríguez MJ, Fernández Rodríguez MI, Gómez Ulla F. Intravitreal Triamcinolone in Diabetic Retinopathy. Current Diabetes Reviews .

  30. 2009Feb 08:)0(6; - .26

  31. Pareja Ríos A, Serrano García M, Quijada Fumero E, Cabrera López F, Abreu Reyes P, Cardona Guerra P, et al. Protocolo para el tratamiento de la Retinopatía Diabética. Arch Soc Canar Oftal [Internet]. 2007 [citado 12 Dic 2000];08)2(:[aprox. 9 p.]. Disponible en: http://www.oftalmo.com/sco/revista-18/18sco02.htm

  32. Ruiz-Moreno JM. Nuevas perspectivas en el abordaje del edema macular diabético. Tratamiento con aflibercept. Arch Soc Esp Oftalmol. 2015 Jun;90(6):24-28.

  33. González Rodríguez NT, Landín Sorí M, Arredondo Torres EL, Chávez Pardo I, González Fernández MC, González Hernández YL. Presentación de caso atípico de glaucoma neovascular .Rev Arch Méd Camagüey. Ene- Feb 2004;08)0(:23-34.

  34. Andonegui J, Serrano L, Eguzkiza A . Oftalmología: estado actual y tendencias futuras. Anales Sis San Navarra. 2010;33(1):659.




2020     |     www.medigraphic.com